Publications by authors named "Ryouetsu Abe"
Nihon Jinzo Gakkai Shi
September 2002
Article Synopsis
- End-stage renal failure patients often suffer from secondary hyperparathyroidism, and a study involving 670 hemodialysis patients highlighted this ongoing issue with many patients already on oral vitamin D3.
- In a follow-up, 92 of these patients received intravenous maxacalcitol, which significantly lowered levels of parathyroid hormone (PTH) and alkaline phosphatase, demonstrating its effectiveness compared to oral vitamin D3.
- However, maxacalcitol treatment was halted for 18.5% of patients due to hypercalcemia, and it was particularly effective in patients with lower serum calcium levels (below 10.5 mg/dl).
